|
Patient Info
Information for Patients
Patients being treated with RHINOCORT AQUA Nasal Spray should receive the following information and instructions. Patients who are on immuno-suppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles and, if exposed, to obtain medical advice. Patients should use RHINOCORT AQUA Nasal Spray at regular intervals since its effectiveness depends on its regular use (see DOSAGE AND ADMINISTRATION).
An improvement in nasal symptoms may be noted in patients within 10 hours of first using RHINOCORT AQUA Nasal Spray. This time to onset is supported by an environmental exposure unit study in seasonal allergic rhinitis patients which demonstrated that RHINOCORT AQUA Nasal Spray led to a statistically significant improvement in nasal symptoms compared to placebo by 10 hours. Further support comes from a clinical study of patients with perennial allergic rhinitis which demonstrated a statistically significant improvement in nasal symptoms for both RHINOCORT AQUA Nasal Spray and for the active comparator (mometasone furoate) compared to placebo by 8 hours. Onset was also assessed in this study with peak nasal inspiratory flow rate and this endpoint failed to show efficacy for either active treatment. Although statistically significant improvements in nasal symptoms compared to placebo were noted within 8Ð 10 hours in these studies, about one half to two thirds of the ultimate clinical improvement with RHINOCORT AQUA Nasal Spray occurs over the first 1Ð 2 days, and maximum benefit may not be achieved until approxi-mately 2 weeks after initiation of treatment. Initial assessment for response should be made during this time frame and periodically until the patient's symptoms are stabilized. Text Continues Below
The patient should take the medication as directed and should not exceed the prescribed dosage. The patient should contact the physician if symp-toms do not improve after two weeks, or if the condition worsens. Patients who experience recurrent episodes of epistaxis (nosebleeds) or nasal septum discomfort while taking this medication should contact their physi-cian. For proper use of this unit and to attain maximum improvement, the patient should read and follow the accompanying patient instructions care-fully. It is important to shake the bottle well before each use. The RHINOCORT AQUA Nasal Spray 32 mcg bottle has been filled with an excess to accom-modate the priming activity. The bottle should be discarded after 120 sprays following initial priming, since the amount of budesonide deliv-ered per spray thereafter may be substantially less than the labeled dose. Do not transfer any remaining suspension to another bottle.
|
.gif)
